One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure
{{output}}
Introduction: Inflammatory bowel disease (IBD) is mainly treated medically, especially with the availability of biological agents. Although anti-TNF drugs have been the only biological drugs available to treat ulcerative colitis ... ...
